

INDEX

- abciximab, 320
- absorption of drugs, 9–15
 - local anaesthetics, 159
 - pharmacokinetic interactions, 40–42
- acarbose, 334
- acebutolol, 214
- ACE inhibitors *see* angiotensin-converting enzyme (ACE) inhibitors
- acetate, 287
- acetazolamide, 297
 - mechanism of action, 297
- acetic acid derivatives, 148–49
- acetylation, 20
- acetylcholine (ACh), 166–68
 - digoxin enhancement of release, 221
 - gastric secretion physiology, 280–81
 - metabolism, 168
 - release, 166, 188
 - structure, 167
 - synthesis, 166, 167
- acetylcholine (ACh) receptor, 2, 3, 166–68
 - occupancy at neuromuscular junction, 35
 - subunits, 2
- acetylcholinesterase (AChE), 166, 168
- acetyl-coenzyme A, 166
- acetyl group, 85, 86
- action potential, 154, 155, 219
 - ACh release, 166
 - cardiac, 218
- activated partial thromboplastin time (APTT), 324
- active transport, 3–5
 - blood–brain barrier, 16
- acupuncture, 279
- acyclovir, 313–14
- adenosine, 223
 - drug interactions, 223
 - kinetics, 223
 - mechanism of action, 223
 - presentation, 223
 - side effects, 223
 - uses, 223
- adenylyl cyclase, 30
- ADP binding inhibition, 319–20
- adrenaline, 191–93
 - effects, 192–93
 - epidural anaesthetics, 14–15
 - kinetics, 193
 - mechanism of action, 192
 - metabolism, 19
 - nebulized, 14
 - presentation and uses, 191–92
- adrenal medulla, 188
- α_1 -adrenergic agonists, 195–97
- β -adrenergic agonists, 197–98
 - β_2 -agonists, inhaled, 14
- adrenergic neurone blockade, 251–53
 - physiology, 251
- adrenoceptor(s), 191, 192
- α -adrenoceptor(s), 192
- β -adrenoceptor(s), 192
- adrenoceptor antagonists, 207–17
 - combined, 216–17
- α -adrenoceptor antagonists, 207–10
 - actions, 208
 - α_1 blockade, selective, 209–10
 - α_2 blockade, selective, 210
 - combined, 216–17
 - non-selective, 207–10
 - selective, 207–10
- β -adrenoceptor antagonists (β -blockers), 210–16, 224–26
 - cardiac effects, 211–12
 - circulatory effects, 212
 - combined, 216–17
 - individual, 214–16
 - intrinsic sympathomimetic activity, 211, 248
 - kinetics, 212
 - membrane stabilizing activity, 211
 - metabolic effects, 212
 - pharmacological properties, 213
 - receptor selectivity, 210–11
 - renin release effects, 247
 - respiratory effects, 212

345 Index

- adrenocorticotrophic hormone (ACTH), 248, 337
- adrenosteroid hormones, 31
- afferent fibres, primary, 126
- affinity of drugs, 32
- after-potentials, 218
- age, drug effects, 23–24
- agonists, 33–35
 - α_1 -agonists, 195–97
 - β -agonists, 197–98
 - full, 33
 - inverse, 33
 - mixed α and β , 200–02
 - partial, 33–35
- albumin, 289–90
 - drug binding, 7, 210
 - functions, 290
 - hypoalbuminaemia, 8
 - kinetics, 290
 - liver function tests, 23
- alcohol dehydrogenase, 19
- aldosterone, 45
- aldosterone antagonists, 295–96
 - effects, 296
 - kinetics, 296
 - mechanism of action, 295
- alfentanil, 136
 - kinetics, 136
 - lipid solubility, 7
 - presentation and uses, 136
- alkane group, 86
- alkanol group, 86
- alkyl group, 87
- alpha blockers *see* α -adrenoceptor antagonists
- alteplase, 329
- aluminium-containing antacids, 280
- alveolar concentration, 108
- alveolar ventilation, 107–08
- amethocaine, topical, 13, 165
- amide group, 87
- amikacin, 310
- amiloride, 295
- amine group, 87
- amino acids, 81
- γ -aminobutyric acid *see* GABA
- aminoglycosides, 310–11
 - kinetics, 310–11
 - mechanism of action, 310
 - side effects, 311
- aminophylline, 202–04
 - drug interactions, 203
 - effects, 203
 - kinetics, 203–04
 - mechanism of action, 203
 - presentation and uses, 202–03
 - toxicity, 204
- aminosteroids, 85
- amiodarone, 228–29
 - drug interactions, 229
 - kinetics, 229
 - mechanism of action, 228
 - side effects, 229
 - warfarin interaction, 41
- amitriptyline, 261–62
- amoxycillin, 303
- AMPA receptor, 27
- amphotericin B, 314–15
- ampicillin, 303
- anaesthesia
 - intravenous, 71–79
 - neuraxial, 328–29
- analgesics, 126–53
 - COX-2 inhibitors
 - preferential, 150
 - specific, 150–53
 - non-specific COX inhibitors, 145–50
 - see also* non-steroidal anti-inflammatory drugs (NSAIDs)
- anaphylactic reactions, thiopental-induced, 99
- angiotensin I, 247
- angiotensin I receptor antagonists (ARAs), 250–51
- angiotensin II, 247–48
- angiotensin II receptor antagonists, 248
- angiotensin-converting enzyme (ACE), 19, 247
- angiotensin-converting enzyme (ACE) inhibitors, 25, 248–49
 - angiotensin I receptor antagonist
 - comparison, 251
- antacids, 280
 - action mechanisms, 25
 - oral, 9
- antagonists, 33, 35–38
 - competitive, 35, 42
 - irreversible, 36
 - non-competitive, 36
 - reversible, 35, 37
- anti-arrhythmics, 218–34
 - digoxin toxicity treatment, 222, 234
 - physiology, 218
 - Vaughan-Williams classification, 219, 220
 - ventricular tachyarrhythmia, 220, 226–28
 - with supraventricular tachyarrhythmias, 228–34

346 Index

- anti-arrhythmics (*cont.*)
 - see also* supraventricular tachyarrhythmias;
 - tachyarrhythmias
- antibacterial drugs/antibiotics, 298, 300
 - aminoglycosides, 310–11
 - broad-spectrum, 316
 - fusidanes, 312–13
 - glycopeptides, 306–07
 - β -lactams *see* β -lactam antibacterial drugs
 - lincosamides *see* lincosamides
 - macrolides *see* macrolides
 - oral contraceptive failure, 22
 - quinolones, 307–09
 - rifamycins, 308
 - targets
 - bacterial cell wall, 300–07
 - DNA and transcription to RNA, 307–09
 - peptide synthesis, 309
- anticholinergics, 275–77
 - effects, 276
- anticholinesterases, 182, 183
 - carbamylated enzyme complex formation, 183–84
 - classification, 182
 - easily reversible inhibition, 182–83
 - organophosphorus compounds, 185
 - physiology, 184
- anticoagulants
 - actions, 318
 - oral, 324–26
 - during pregnancy, 17
- anticonvulsants, 265–69
- antidepressants, 260–65
 - atypical agents, 264–65
 - effects, 262
- antidiuretic hormone (ADH), 248
- antiemetics, 270–79
 - 5-HT₃ antagonists, 277–78
 - acupuncture, 279
 - antihistamines, 277
 - benzodiazepines, 279
 - dopamine antagonists, 271–75
 - types, 270
- antifibrinolytics, 330
- antifungal drugs, 314–15
 - amphotericin B, 314–15
 - azoles *see* azoles
 - polyenes, 314
- antihistamines, 277
- antihypertensives, 247–56
 - ACE inhibitors *see* angiotensin-converting enzyme (ACE) inhibitors
 - adrenergic neurone blockade, 251–53
 - centrally acting drugs, 253–56
 - renin–angiotensin–aldosterone system drugs, 247–51
- antimicrobial agents, 298–316
 - antibacterial drugs *see* antibacterial drugs/antibiotics
 - antifungal drugs *see* antifungal drugs
 - antiviral drugs, 313–14
 - ICU considerations, 315–16
 - renal replacement therapy and, 316
- antimuscarinics, 275
- antiplatelet drugs, 318–21
- antithrombin III, 317
- antiviral drugs, 313–14
- anxiolytics, 257–60
- apixoban, 328
- aprepitant, 278–79
- aprotinin, 330
- area under the curve (AUC), 54, 62, 64
- β -arrestin, 30
- aspirin, 145, 318–19
 - absorption, 9
 - ionization, 6
 - kinetics, 146
 - mechanism of action, 145
 - metabolic effects, 145
 - overdose, 145–46
 - sodium bicarbonate treatment, 42
 - structure, 145
 - thromboembolism prevention, 142
 - uses, 145
- asthma, NSAID-sensitive, 143
- asymptote, 52
- atenolol, 214
- atipamezole, 256
- atracurium, 48, 84, 179–80
 - cisatracurium, 19, 180
 - kinetics, 180
 - presentation and uses, 179
- atrioventricular nodal re-entrant tachycardia, 220
- atropine, 276–77
 - blood–brain barrier crossing, 16
 - effects, 276
 - kinetics, 277
 - racemic, 49
 - uses, 276
- autonomic nervous system, 187, 188
 - transmitters, 188
- azithromycin, 309
- azoles, 315

347 Index

- kinetics, 315
- mechanism of action, 315
- aztreonam, 305
- bacterium, 299
 - common pathogens, 301
 - see also* antibacterial drugs/antibiotics
- barbiturates, 83, 96
 - intravenous use, 97–101
 - keto-enol transformation, 98
 - lipid solubility and protein binding, 97
- barbituric acid, 98
- bendroflumethiazide, 292–94
- benign prostatic hyperplasia (BHP), 42
- benzamides, 274–75
- benzodiazepines, 84, 257–58, 267
 - kinetics, 259
 - structure, 257–58
- benzyl group, 87
- benzylpenicillin, 303
- beta (β) agonists, 197–98
 - inhaled, 14
- beta (β) blockers *see* β -adrenoceptor antagonists
- betamethasone, 336
- bicarbonate, 290
 - see also* sodium bicarbonate
- bi-exponential decline, 61
- biguanides, 333–34
- biliary excretion, 22
- bioavailable fraction (FB), 10
- bioavailability
 - area under the curve, 10
 - extraction ratio, 11–12
 - factors influencing, 10–11
 - oral administration, 10–11
- birth, distribution of drugs, 17–18
- blood–brain barrier
 - active transport, 3–5
 - anticholinergics crossing, 275
 - drug distribution, 16
 - mannitol crossing, 296
 - tight junctions, 1
- blood:gas partition coefficient, inhaled
 - anaesthetics, 108, 109–10
- body fluid compartments, 286
- bosentan, 246
- Bowman's principle, 5
- bradyarrhythmias, 219
- bradykinin, raised levels, 25
- brain
 - local anaesthetic penetration, 159
 - see also* blood–brain barrier
- Bristol model of TIVA, 73
- bronchial airways, 14
- bronchodilators, nebulized, 14
- bumetanide, 294–95
- bupivacaine, 162–63
 - cardiac effects, 158–59
 - enantiopure preparations, 49
 - epidural analgesia, 17
 - intravenous regional anaesthesia, 160
 - ionization, 6
 - kinetics, 163
 - presentation and uses, 162–63
 - racemic, 48–49
- buprenorphine, 33, 141
- butyrophenones, 273–74
- calcium, 291
 - interaction with sodium bicarbonate, 40
 - salts, 206
- calcium ion channel(s)
 - cardiac action potential, 218
 - insulin release, 331
 - L-type, 240
 - verapamil effects, 224
- calcium ion channel antagonists, 240–44
 - cardiovascular effects, 241, 242, 243
 - classification, 240, 241
 - pharmacological properties, 240, 242
- cAMP, 30–31
- cannabinoids, 279
- captopril, 249
- carbamazepine, 266–67
- carbamyl group, 87
- carbapenems, 305–06
- carbimazole, 340
- carbon-based compounds, 80
- carbon dioxide, 124–25
 - absorbents, 125
 - effects, 125
 - physiochemical properties, 124
 - uses, 125
- carbonic anhydrase inhibitors, 297
- carboprost, 343
- carboxylic acid group, 87
- cardiac action potential, 218
- cardiac arrhythmias, 218–19
 - succinylcholine effect, 171
 - see also* anti-arrhythmics; *specific arrhythmias*
- cardiac output
 - drugs decreasing, 41
 - inhaled anaesthetics, 108

348 Index

- catecholamines, 82
 - naturally occurring, 189–95
 - synthesis, 190
- catechol group, 88
- catechol O-methyl transferase (COMT), 82
 - adrenaline metabolism, 193
 - adrenergic neurone blockade, 251
 - dopamine kinetics, 195
 - isoprenaline metabolism, 198
- cefotaxime, 304
- ceftazidime, 304
- ceftriaxone, 304
- cefuroxime, 304
- celecoxib, 152
- cell membrane
 - active transport, 4
 - drug passage, 1–8
 - methods of crossing, 1–5
 - structure, 1, 2
- centrally acting drugs, 253–56
- central nervous system (CNS)
 - drugs affecting, 257–69
 - anticonvulsants, 265–69
 - antidepressants, 260–65
 - anxiolytics, 257–60
 - hypnotics, 257–60
 - physiology, 257–69
- central venous access, 9
- cephalosporins, 302, 304–05
 - classification, 305
 - first-generation, 304, 305
 - kinetics, 304
 - mechanism of action, 304
 - second-generation, 305
 - side effects, 305
 - third-generation, 304
- cephradine, 304
- cGMP, 31
- chelating agents, 25, 41
- chemoreceptor trigger zone, 270
- children, 23–24
 - propofol contraindication, 103
 - see also* neonates
- chiral centres, 47, 157
 - more than one, 48
 - single, 47–48
- chloride ion(s), 292, 294–95
- chloride ion channels, ligand-gated, 33
- chlorothiazide, 292–94
- chlorpromazine, 271–72
 - effects, 272
 - kinetics, 272
 - mechanism of action, 272
 - uses, 271
- choline, 166
- choline group, 88
- cholinesterase
 - neonates, 24
 - plasma
 - genetic variants, 174, 175
 - inhibition, 174
 - mivacurium metabolism, 181
 - succinylcholine metabolism, 20
 - variants, 20
- cilastatin, imipenem combination, 305
- cimetidine, 42, 281, 333
 - effects, 281
 - kinetics, 281
 - uses, 281
- ciprofloxacin, 307
- circus mechanisms, 219
- cisatracurium, 19, 180
- clarithromycin, 309
- clavulanic acid, 303
- clearance of drug, 55, 62, 65
 - constant relationships, 65
 - inter-compartmental rates, 65
 - rate constant, 51, 55–59
 - volume of distribution, 63–65
- clonidine, 254–55
 - effects, 254–55
 - kinetics, 255
 - mechanism of action, 254
 - presentation and uses, 254
- clopidogrel, 319–20
- clotting factors, 318, 321
 - unfractionated heparin mechanism of action, 322–23
- coagulation
 - cascade, 317, 318
 - cell-based model, 317–18
 - classical model, 317
 - drugs affecting, 317–30
 - antiplatelet drugs, 318–21
 - oral anticoagulants, 324–26
 - initiation, amplification, propagation, 318
 - physiology, 317
- cocaine, 164–65
 - kinetics, 165
 - mechanism of action, 164
 - presentation and uses, 164
 - side effects, 165

349 Index

- codeine, 86, 133–34
 - kinetics, 134
 - poor metabolizers, 134
 - uses, 133
- colloids, 287–90
- compartmental models, 50, 55–62, 63
- concentration effect, 109
- concentration gradient, 5
- concentration of drug, 50, 55
 - plasma, 50
 - differentiation, 54
 - dose required, 66
 - natural logarithms, 54
- concentration-time curve, 62
- Conn's syndrome, 295
- constants, relationships, 65
- context sensitive half-time, 76–78
 - propofol, 77
 - remifentanyl, 72
- corticosteroids *see* glucocorticoid(s); steroids
- corticotrophin-releasing hormone, 337
- cortisone, 31
- covalent bonds, 80
- COX-1 inhibitors, 318–19
- COX-2 inhibitors
 - preferential, 150
 - specific, 150–53
 - structure, 151
- COX inhibitors, non-specific, 145–50
- cranial nerves, 187
- creatinine clearance, 22
 - elderly people, 24
 - neonates, 24
- critical illness myopathy, 177
- critical volume hypothesis, 94
- crystalloids, 287
- cyanide, 236–37
 - poisoning, 25
 - toxicity, 237
- cyclizine, 277
- cyclodextrin(s), 185
- γ cyclodextrin, 25, 185
- cyclohexanol group, 88
- cyclo-oxygenase (COX), 142–43
 - see also* COX-1 inhibitors; COX-2 inhibitors; COX inhibitors
- cytochrome P450 system, 19, 42
 - inhaled anaesthetics, 110
 - neonates, 24
 - repaglinide, 335
- dabigatran, 326–27, 328
- dalteparin, 323
- dantrolene, 173–74
 - kinetics, 174
 - malignant hyperthermia treatment, 173
 - mechanism of action, 174
- DC cardioversion, digoxin, 222
- decrement time for TCI, 76
- δ receptors, 128
- depolarization, sino-atrial node, 218
- depot preparations, 13
- desensitization, 38
- desflurane, 106, 120–21
 - effects, 120–21
- dexamethasone, 279, 336
- dexmedetomidine, 255–56
 - enantiopure preparations, 49
- dextran 70, 321
- dextrose, interaction with insulin, 40
- diabetes mellitus
 - drugs used in, 331–35
 - glucocorticoid-induced, 336
 - peri-operative patient care, 335
 - sulphonylureas, 332–33
 - thiazide diuretics, 292–94
- diacylglycerol (DAG), 30
- diamorphine, 18, 86, 131–33
 - intrathecal, lipid solubility, 7
 - kinetics, 133
 - presentation and uses, 133
- diastereoisomers, 48
- diazepam, 259
 - metabolism, 261
- diazoxide, 245–46
- dibucaine, 174
- diclofenac, 148–49
 - effects, 148
 - kinetics, 149
 - presentation and uses, 148
- dicobalt edetate, 25, 41, 237
- differentiation, 50, 54
- diffusion rate
 - concentration gradient, 5
 - factors influencing, 5–8
 - ionization, 5–6
 - lipid solubility, 6–7
 - molecular size, 5
 - protein binding, 7–8
- digoxin, 221–22
 - drug interactions, 222
 - hypokalaemia risk, 293

350 Index

- digoxin (*cont.*)
 - kinetics, 222
 - mechanism of action, 221
 - presentation, 221
 - side effects, 221–22
 - toxicity, 222
 - treatment, 222, 234
 - uses, 221
- dihydrocodeine, 45, 134
- diltiazem, 243–44
- dipyridamole, 319
- direct factor Xa inhibitors, 327–29
- diseases
 - bioavailability influence, 10–11
 - co-existing in elderly people, 24
 - effects on drug actions, 22–23
- disopyramide, 231–32
 - kinetics, 232
 - mechanism of action, 231–32
 - presentation and uses, 231
 - side effects, 232
- distribution of drugs, 15
 - birth, 17–18
 - extensive, 15
 - fetal, 16–18
 - limited, 15
 - local anaesthetics, 159
 - neonates, 23–24
 - pharmacokinetic interactions, 40–42
 - in pregnancy, 17
- diuretics, 292–97
 - carbonic anhydrase inhibitors, 297
 - groups, 292
 - loop, 294–95
 - osmotic, 296–97
 - potassium-sparing, 295
 - sites of action, 293
 - thiazides, 92, 292–94
- dobutamine, 45, 198
 - effects, 198
 - kinetics, 198
 - presentation and uses, 198
- domperidone, 274, 284
- DOP (δ receptors), 128
- dopamine, 194–95
 - effects, 194–95
 - kinetics/metabolism, 19, 195
 - mechanism of action, 194
 - presentation and uses, 194
 - receptors, 270
- dopamine antagonists, 271–75
 - effects, 273
- dopexamine, 198–99
 - effects, 199
 - mechanism of action, 199
 - presentation and uses, 198
- dose-ratio, 35
- dose-response curves, 37
- dothiepin, 261–62
- double burst stimulation, 170
- doxycycline, 311
- droperidol, 273–74
 - effects, 274
 - kinetics, 274
 - uses, and mechanism, 273
- drug(s)
 - design, 80
 - molecules, 86–92
 - passage across cell membrane, 1–8
 - structures, 82–86
- drug action mechanisms, 25–31
 - dependent on chemical properties, 25
 - enzymes, 25
 - receptors, 26–31
 - voltage-gated ion channels, 25
- drug interactions, 40–44
 - pharmaceutical, 40
 - pharmacodynamic, 42–44
 - pharmacokinetic, 10, 40–42, 65–66
 - potentiation, 43
 - summation, 43
 - synergism, 44
- drug receptors
 - binding dynamics, 32–33
 - interaction types, 32
- ecothiopate iodide, 185
- edrophonium, 182–83
 - kinetics, 182
 - mechanism of action, 182
 - uses, 182
- elderly people
 - co-existing diseases, 24
 - drugs influences, 24
- elimination, constant relationships, 64, 65
- elimination rate constant, 62
- EMLA, topical, 13, 162
 - cautions, 162
 - presentation and uses, 162
- enalapril, 18, 250
- enantiomers, 48
 - racemic mixtures, 48–49
 - single, 48
- enantiopure preparations, 49
- enflurane, 45, 106, 120
- enol group, 88

351 Index

- enoxaparin, 323
- enoximone, 204–05
 - effects, 204–05
 - kinetics, 205
 - mechanism of action, 204
 - presentation and uses, 204
- enterohepatic circulation, 22
- Entonox, 113
 - see also* nitrous oxide
- enzymes
 - action mechanisms, 25
 - hepatic microsomal, 21
 - induction, 20, 42
 - inhibition, 20, 25
 - neonates, 24
- ephedrine, 200–01
 - effects, 201
 - kinetics, 201
 - mechanism of action, 201
 - presentation and uses, 201
- epidural analgesia, bupivacaine, 17
- epidural route, 14–15
- epilepsy, medication in pregnancy, 17
- epoprostenol, 321
- eptifibatide, 320
- ergometrine, 342–43
- erythromycin, 309
 - alfentanil concurrent administration, 136
- esmolol, 214–15, 225
 - kinetics, 225
 - side effects, 225
- esterases, 19, 24
- esters, 88
 - hydrolysis, atracurium, 180
- ethanol, metabolism, 19
- ether link, 88
- etomidate, 96, 105–06
 - effects, 105–06
 - GABA_A receptor, 96
 - kinetics, 106
 - presentation and uses, 105
- etoricoxib, kinetics, 153
- eutectic mixture of local anaesthetic *see* EMLA, topical
- excretion of drugs, 20–22
 - biliary, 22
 - drug interactions, 42
 - neonates, 24
 - renal, 21–22
- exponential function, 50–52
 - half life, 51
 - time constant, 51
- exponential wash-out curve, semilogarithmic transformation, 58
- exponents, 51
- extraction ratio, 11–12
- Fab, digoxin-specific, 222
- facilitated diffusion, 3
 - blood–brain barrier, 16
- factor Xa inhibitors, direct, 327–29
- 'fade', 167, 169
- famotidine, 282
- felypressin, epidural anaesthetics, 15
- fentanyl, 135–36
 - Bristol model of TIVA, 73
 - context sensitive half-time, 76
 - kinetics, 135–36
 - lipid solubility, 7
 - presentation, 135
 - uses, 135
- fetus, drug distribution, 16–18
- fibrin, 317
- fibrinolytics, 329–30
- fibrinolytic system, 317
 - drugs affecting, 329–30
- Fick's law, 5
- first-pass metabolism, 10
 - avoidance, 12
 - bioavailability influence, 10
- flecainide, 230
 - kinetics, 230
 - mechanism of action, 230
 - presentation and uses, 230
 - side effects, 230
- fluconazole, 315
- fluid compartments, 286
 - distribution processes, 286–87
 - neonates, 23
- fluid replacement, 286–87
- flumazenil, 42, 260
- fluoxetine, 263
- fosaprepitant, 278–79
- functional residual capacity (FRC), 107
- fungi, 298, 299
- furosemide, 294–95
- fusidanes, 312–13
- fusidic acid, 312
- GABA, 81
 - agonist sites, 95
- GABA_A receptor, 2, 26, 95–96, 257
 - benzodiazepine effects, 36
- GABA_A receptor complex, 95
- GABA_B receptors, 257

352 Index

- gabapentin, 268
- gallamine, 22
- gastric motility, drugs affecting, 283–84
- gastric secretion
 - drugs influencing, 280–82
 - physiology, 280–81
- gate theory of pain, 126, 127
- gelatins, 287–89
 - formulation, 288
 - kinetics, 288–89
 - side effects, 289
- general anaesthesia, MAOIs and, 264
- general anaesthetic agents, 93–125
 - anatomical sites of action, 93
 - lipid solubility, 93–94
 - mechanisms of action, 93–96
 - molecular theories, 93–94
 - protein sites of action, 94–96
 - see also* inhaled anaesthetics; intravenous anaesthetics
- genetic polymorphism, 20
- gene transcription regulation, 31–32
- gentamicin, 310
- giving set interactions, 40
- glibenclamide, 332
- gliclazide, 332
- glipizide, 332
- globulin, drug binding, 7
- glomerular filtration, 21
- glucagon, 205
- glucocorticoid(s), 336–43
 - adrenal suppression, 337
 - anti-inflammatory effects, 336–37
 - fluid retention, 337
 - immunosuppressive effects, 337
 - metabolic effects, 336
 - perioperative supplementation, 337–38
 - receptor, 31
 - vascular reactivity, 337
- glucose, 82
 - absorption, 3
 - blood–brain barrier crossing, 16
 - insulin release, 331
 - see also* hypoglycaemic agents
- glucuronidase, 22
- glucuronidation, 19
- glucuronide group, 88
- glutamate, 81
 - ionotropic, 27–28
 - ketamine antagonism, 96
- glyceryl trinitrate, 237–39
 - effects, 238
 - kinetics, 238–39
 - mechanism of action, 238
 - presentation, 237
 - uses, 237
- glycine, 81
 - receptors, 96
- glycopeptides, 306–07
 - mechanism of action, 306
- glycoprotein IIb/IIIa receptor antagonists, 320–21
- glycopyrrolate, 16, 277
- G-protein(s), 28–30
 - α subunit, 28, 30
- G-protein coupled receptors (GPCRs), 28, 29
 - adrenaline action, 191
- Graham's law, 5
- Gram-negative bacilli, 301, 302, 303
- Gram-positive cocci, 301, 302
- guanethidine, 252
- guanylyl cyclase, membrane, 31
- gut, drugs acting on, 280–85
 - antacids, 280
 - drugs affecting gastric motility, 283–84
 - drugs influencing gastric secretion, 280–82
 - mucosal protectors, 284
 - prostaglandin analogues, 284–85
- haemostasis, 318
- half-life, 51, 54
 - natural logarithms, 54
 - terminal elimination, 62, 76–78
- halogen group, 88
- halothane, 106, 117–20
 - effects, 118
 - metabolism, 118
 - toxicity, 120
- Hartmann's solution, 287
- heart valves, artificial, medication during
 - pregnancy, 17
- helium, 124
- Henderson-Hasselbalch equation, 6
- heparins
 - low molecular weight, 323–24
 - therapy monitoring, 324
 - unfractionated, 322–23
 - kinetics, 323
 - mechanism of action, 322–23
 - side effects, 323
 - uses, 322
- hepatic encephalopathy, 23
- hepatic enzymes
 - first-pass metabolism, 10
 - microsomal, 21
- hepatocytes, rapid uptake of drugs, 12
- heterocyclic groups, 47, 88

353 Index

- hexobarbitone, 96
- Hofmann degradation, 19, 84
 - atracurium, 180
 - cis-atracurium, 19, 180
- homovanillic acid, dopamine kinetics, 195
- hormone replacement therapy, 341–42
- 5-HT₃ antagonists, 277–78
- 5-HT₃ receptor, 26
- hydralazine, 244
 - effects, 244
 - kinetics, 244
 - mechanism of action, 244
 - presentation and uses, 244
- hydrocortisone, perioperative supplementation, 337–38
- hydrolysis, 18
- hydroxyethyl starches, 289
 - formulation, 289
 - kinetics, 289
 - side effects, 289
- hyoscine, 275–76
 - effects, 275
 - kinetics, 276
 - uses, 275
- hyperkalaemia
 - aldosterone antagonists, 295–96
 - calcium salts, 206
 - digoxin induced, 222
 - potassium-sparing diuretics, 295
 - succinylcholine-induced, 172
- hyperthermia *see* malignant hyperthermia
- hyperthyroidism, drug use, 340
- hypnotics, 257–60
 - non-benzodiazepine, 260
- hypoalbuminaemia, 8
- hypoglycaemic agents, 331–35
 - acarbose, 334
 - biguanides, 333–34
 - meglitinides, 335
 - sulphonylureas, 332–33
 - thiazolidinediones, 334
 - see also* insulin
- hypokalaemia, thiazides with
 - digoxin, 293
- hypothalamus, 187
- ibuprofen, 149–50
 - dose, 149
 - kinetics, 150
 - presentation, 149
 - side effect profile, 149
- imidazoles, 88, 315
- imipenem, 305
- imipramine, 261–62
- indomethacin, 86
- infants, 23–24
- infected tissue, local anaesthetics, 157
- inflammation, protein binding, 7
- infusion rate, 50
- inhalation route, 14
 - local site of action, 14
 - systemic site of action, 14
- inhaled anaesthetics, 106–21
 - alveolar ventilation, 107–08
 - biochemical characteristics, 107
 - blood–brain barrier crossing, 16
 - blood:gas partition coefficient, 109–10
 - cardiac output, 108
 - cardiovascular effects, 118, 122
 - concentration, 110
 - ideal, 106
 - kinetics, 107–10
 - metabolism, 110
 - partial pressure, 106, 107
 - pharmacology, 110–21
 - physical characteristics, 106–07
 - physicochemical properties, 115
 - respiratory effects, 118, 122
 - structure, 114
- inositol triphosphate (IP₃), 30
- inotropic agents, 202–06
- inspired concentration, 108
- insulin, 331–32
 - blood–brain barrier crossing, 16
 - copreparation with zinc/protamine, 13
 - interaction with dextrose, 40
 - physiology, 331
 - preparations, 331–32
 - receptor, 31
 - side effects, 332
 - synthesis, 332
 - variable rate insulin infusion, 335
- integration, 50, 54–55
- intensive care, nitric oxide use in adults, 124
- intermediate messengers, 28–31
- intermittent boluses, accumulation of
 - drug, 57
- international normalized ratio (INR), 23, 326
- interstitial volume, 286
- intestinal mucosa
 - active transport, 4
 - tight junctions, 1
- intracellular sequestration, 64
- intracellular volume, 286
- intramuscular route, 12–13

354 Index

- intra-ocular pressure, succinylcholine-induced, 172
- intrathecal route, 15
- intravascular volume, 286
- intravenous administration, 9
 - regional anaesthesia, 160
- intravenous anaesthetics, 97–106
 - barbiturates, 97–101
 - blood–brain barrier crossing, 16
 - chemical structure, 102
 - ideal agents, 71–79
 - non-barbiturates, 101–06
 - pharmacokinetics, 102
 - pharmacological properties, 104
 - propofol, 71–72
 - remifentanyl, 72–73
- intravenous fluids, 287–88
 - colloids, 287–90
 - composition, 288
 - crystalloids, 287
 - minerals, 290–91
- intrinsic activity of drugs, 33
- iodides, 341
- ion channel(s), 2
 - voltage-gated, 25
- ion channel receptors, ligand-gated, 26–28
 - families, 26–28
 - pentameric family, 26
- ionization, 5–6
- ion tapping, bupivacaine, 17
- isobologram, 43, 44, 75
- isocarboxazid, 263–64
- isoflurane, 45, 106, 113–16
 - effects, 114–16
 - metabolism, 116
 - toxicity, 116
- isomerism, 45–49
 - geometric, 46–47
 - structural, 45, 46
- isomers
 - mixtures, 49
 - optical, 47–48
 - racemic mixtures, 48–49
 - structural, 46
- isoprenaline, 45, 197–98
 - effects, 197–98
 - kinetics, 198
 - presentation and uses, 197
- isoquinolones, 89
- isosorbide dinitrate, 239
- isosorbide mononitrate, 239
- itraconazole, 315
- juxtaglomerular apparatus, 247
- kainate receptor, 27
- ketamine, 36, 96, 103–05
 - effects, 103–05
 - enantiopure preparations, 49
 - kinetics, 105
 - presentation and uses, 103
- ketoconazole, 315
- keto-enol transformation, 45, 98
- keto groups, 89
- ketorolac, 149
- kidney
 - juxtaglomerular apparatus, 247
 - see also* renal disease
- kinetics
 - non-linear, 65–66
 - see also* pharmacokinetics
- KOP (κ receptors), 128
- labetalol, 216–17
- labour, distribution of drugs, 17–18
- β -lactam antibacterial drugs, 300
 - carbapenems, 305–06
 - monobactams, 305
 - see also* cephalosporins; penicillins
- β -lactam ring, 302
- β -lactamase, 302, 304
- lactate, 287
- lamotrigine, 267–68
- lansoprazole, 283
- laudanosine, 89
- lead-compounds, 80
- levobupivacaine, 163
 - presentation and uses, 163
 - toxicity profile, 163
- Lewis acids, 116
- lidocaine, 159, 160–62, 226–27
 - epidural route, 15
 - intravenous regional anaesthesia, 160
 - kinetics, 162, 227
 - mechanism of action, 227
 - preparations, 160
 - presentation, 226
 - side effects, 227
 - uses, 227
 - ventricular arrhythmia treatment, 158–59
- ligands
 - natural, 26
 - receptor binding, 29, 32–33
- lincosamides, 311
 - mechanism of action, 311

355 Index

- side effects, 311
- linezolid, 264
- lipid sites, 94
- lipid solubility, 6–7
 - barbiturates, 97
 - general anaesthetic agents, 93–94
 - local anaesthetics, 155, 156
 - MAC relationship, 94
- lipophilic areas, 93–94
- lisinopril, 249
- lithium carbonate, 265, 341
- liver
 - active transport, 4
 - disease, 23
 - function tests, 23
 - NSAID toxicity, 144
- local anaesthetics, 154–65
 - absorption, 159
 - cardiac effects, 158–59
 - central nervous system effects, 158
 - classification, 156
 - distribution of drugs, 159
 - duration of action, 156
 - elimination, 159
 - infected tissue, 157
 - kinetics, 159–60
 - lipid solubility, 155, 156
 - mechanisms of action, 155, 156
 - metabolism, 159–60
 - onset of action, 156
 - pharmacological properties, 161
 - physiochemical characteristics, 155–58
 - physiology, 154, 157
 - potency, 156
 - preparations, 154–55
 - protein binding, 156, 159
 - sodium ion channel binding, 3
 - structure, 157
 - toxic doses, 160
 - vasodilator activity, 156
- logarithmic function, 52–54
- logarithms, 52–54, 67–70
 - natural, 54
 - semilogarithmic transformation, 58
- loop diuretics, 294–95
 - effects, 294–95
 - kinetics, 295
 - mechanism of action, 294
- lorazepam, 259
 - antiemetic use, 279
- losartan, 250–51
- lungs, surface area, 14
- macrolides, 309–10
 - drug interactions, 310
 - kinetics, 309
 - mechanism of action, 309
 - side effects, 310
- magnesium, 290–91
 - uses, 290–91
- magnesium-containing antacids, 280
- malabsorption syndromes, bioavailability
 - influence, 10
- malignant hyperthermia, 173
 - diagnosis, 173
 - mechanism, 173
 - safe drugs, 173
 - treatment, 173
- mandelic acid, 89
- mannitol, 296–97
 - effects, 296
 - kinetics, 296–97
 - mechanism of action, 296
- Marsh model of TCI, 74
- mathematical models, 50
- mean residence time (MRT), 63
 - volume of distribution, 63
- medical gases, non-anaesthetic, 121–25
- medicinal chemistry, 80–92
- meglitinide, 335
- meloxicam, 150
 - kinetics, 150
- membrane expansion, 155
- membrane lipids, 93–94
- meropenem, 305
- metabolic capacity, drugs with
 - low level, 12
- metabolism of drugs, 18–20
 - drug interactions, 41–42
 - enzyme induction/inhibition, 20
 - genetic polymorphisms, 20
 - neonates, 24
 - phase I, 18–19
 - phase II, 19
- metabolites, 18
- metaraminol, 201–02
- metformin, 333–34
- methadone, 139
 - kinetics, 139
- methaemoglobinaemia
 - prilocaine, 164
 - risk with EMLA, 162
- methicillin-resistant *Staphylococcus aureus* (MRSA), 298
 - clindamycin activity, 311

356 Index

- methohexitone, 96
- methoxamine, 45
- methoxy group, 89
- methoxyflurane, 18
- methyl group, 89
- methylation, 19
- methyldopa, 253–54
 - effects, 253
 - kinetics, 254
 - mechanism of action, 253
 - presentation and uses, 253
- methylprednisolone, 336
- metirosine, 252–53
- metoclopramide, 40, 274–75, 283–84
 - effects, 275, 283–84
 - kinetics, 275, 284
 - mechanism of action, 274, 283
 - uses, 274, 283
- metolazone, 292–94
- metoprolol, 215
- metronidazole, 308–09
 - kinetics, 309
 - mechanism of action, 308–09
 - side effects, 309
- mexiletine, 227–28
 - kinetics, 228
 - mechanism of action, 228
 - side effects, 228
- mianserin, 264–65
- Michaelis constant, 11
- miconazole, 315
- midazolam, 45, 84, 258–59
 - alfentanil concurrent administration, 136
 - kinetics, 258–59
 - presentation, 258
 - propofol co-administration, 43, 78
 - uses, 258
- milrinone, 205
- mineralocorticoid receptor, 31
- minerals, 290–91
 - calcium, 291
 - magnesium *see* magnesium
 - phosphorus, 291
- minimum alveolar concentration (MAC), 106, 107
 - lipid solubility, 94
- minocycline, 311
- minoxidil, 245
- misoprostil, 284–85
 - effects, 285
 - kinetics, 285
 - uses, 284
- mivacurium, 47, 84, 180–81
 - kinetics, 181
 - presentation and uses, 181
- moclobemide, 264
- molecular size, diffusion rate, 5
- molecule–protein complex, 3
- monoamine oxidase, 19, 82
 - adrenaline metabolism, 193
 - adrenergic neurone blockade, 251
 - blood–brain barrier, 16
 - dopamine kinetics, 195
 - noradrenaline kinetics, 194
- monoamine oxidase inhibitors (MAOI), 42, 263
 - general anaesthesia, 264
 - non-selective irreversible, 263–64
 - pethidine and, 42
 - selective reversible, 264
- monobactams, 305
- N-monomethyl-L-arginine (L-NMMA), 123
- MOP (μ receptors), 127–28
- morphine, 128–31, 134
 - effects, 130–31
 - keto-enol transformation, 45
 - kinetics, 131
 - metabolism, 131
 - presentation and uses, 128–30
- motor nerves, unmyelinated, 166
- moxifloxacin, 307
- mucosal protectors, 284
- multi-compartment models, 59, 63
 - clearance of drug, 65
 - volume of distribution, 64
- muscle mass, elderly people, 24
- muscle relaxants, 166–86
 - blood–brain barrier crossing, 16
 - depolarizing, 168, 170–75
 - tetanic stimulation, 169
 - non-depolarizing, 175–86
 - aminosteroids, 85
 - bis-benzylisoquinolinium, 47, 84
 - classification, 175
 - competitive inhibitions, 35
 - kinetics, 181
 - in labour, 18
 - neostigmine use, 184
 - patterns of block, 169
 - properties, 178
 - single twitch stimulation, 168
 - structure, 176
 - tetanic stimulation, 169
 - train-of-four, 170
- pharmacological/physiological interactions, 175, 177
- physiology, 166

357 Index

- μ receptors, 127–28
 - myalgia, succinylcholine-induced, 172
 - myopathy
 - atracurium-induced, 179
 - critical illness, 177
- Na⁺/amino acid symport, 4
- nabilone, 279
- Na⁺/K⁺ ATPase, 4, 154
 - digoxin inhibition, 221
- nalbuphine, 141
- nalidixic acid, 307
- naloxone, 86, 140
- nausea, 270
 - domperidone use in children, 284
 - physiology, 270
 - see also* antiemetics
- neomycin, 310
- neonates, 23–24
 - enzyme systems, 24
- neostigmine, 183
- neurokinin 1 (NK₁) receptor antagonists, 278–79
- neuromuscular block
 - monitoring, 168–70
 - partial, 168, 171
 - phase I and phase II, 171
 - types, 168
- neuromuscular junction
 - acetylcholine receptor, 26, 35
 - antagonists, 35
 - stimulation patterns, 168
 - structure, 166
 - succinylcholine effects, 171
- neurotransmitters, 81
 - general anaesthetic effects, 95
 - inhibitory and excitatory, 95
 - see also specific neurotransmitters*
- nicorandil, 239–40
 - effects, 239–40
 - kinetics, 240
 - mechanism of action, 239
 - presentation and uses, 239
- nicotinic acetylcholine receptor, 26
- nifedipine, 241–43
- nimodipine, 243
- nitrates, 237–39
 - organic, 123
 - tolerance, 39
- nitric oxide (NO), 122–24
 - adult intensive care use guidelines, 124
 - effects, 123
 - guanylyl cyclase stimulation, 31
 - inhaled, 14
 - synthesis, 123
- nitric oxide synthase (NOS), 123
- nitrites, 237–39
- nitroimidazoles, 308–09
- nitrous oxide (N₂O), 110–13
 - concentration effect, 109, 111–12
 - diffusion hypoxia, 112
 - effects, 111
 - manufacture, 110–11
 - second gas effect, 112
 - storage, 111
 - toxicity, 112–13
- nizatidine, 282
- NMDA receptor, 2, 27, 96
 - ketamine antagonism with glutamate, 36
- L-NMMA, 123
- non-compartment models, 62–63
 - volume of distribution, 64
- non-linear kinetics, 66
- non-steroidal anti-inflammatory drugs (NSAIDs), 126, 141–44
 - asthma, 143
 - classification, 141
 - clinical data, 144
 - drug interactions, 144
 - gastric irritation, 143
 - hepatotoxicity, 144
 - kinetics, 144
 - mechanisms of action, 142–43
 - platelet function, 144
 - renal function, 144
 - vascular events, 143
- NOP receptor, 128
- noradrenaline, 193–94
 - effects, 193–94
 - kinetics and metabolism, 19, 194
 - mechanism of action, 193
 - presentation and uses, 193
 - release, 189
- nortriptyline, 261–62
- nucleic acids, 81
- nucleosides, 81
- nucleotides, 81
- oestrogen, 341–42
- omeprazole, 282–83
 - effects, 282–83
 - kinetics, 283
 - mechanism of action, 282
 - uses, 282
- ondansetron, 277–78
 - effects, 278
 - kinetics, 278

Cambridge University Press
978-1-107-65726-7 — Pharmacology for Anaesthesia and Intensive Care

T. E. Peck, S. A. Hill

Index

[More Information](#)

358 Index

- ondansetron (*cont.*)
 - mechanism of action, 278
 - presentation and uses, 278
- one-compartment model, 55–59
 - clearance of drug, 65
 - volume of distribution, 64
- opioids, 85–86, 127–40
 - doses, 133
 - minimizing use, 270
 - partial agonists, 140–41
 - pharmacological properties, 127, 132
 - receptors, 127–28, 130
 - structure, 129
- oral administration, 9–12
 - bioavailability, 10–11
- oral contraceptives, 341
 - failure with antibiotics, 22
 - mechanism of action, 341
 - side effects, 341
- organic chemistry, 80
- organophosphorus compounds, 185, 186
- osmotic diuretics, 296–97
- oxicam group, 90, 150
- oxidation, 18
- oxycodone, 137–38
 - common preparations, 137
 - mechanism of action, 137
 - uses, 138
- oxygen, 121–22
 - effects, 122
 - manufacture and storage, 121–22
 - measurement, 122
 - physiochemical properties, 122
 - toxicity, 122
- oxytetracycline, 311
- oxytocic drugs, 342–43
- oxytocin, 342
 - mechanism of action, 342
 - presentation and uses, 342
 - side effects, 342
- pain, 126
 - modification, 126
 - physiology, 126
- pancuronium, 179
 - kinetics, 179
 - presentation and uses, 179
 - volume of distribution, 179
- papaverine, 84, 90
- para-aminophenols, 146–48
- paracetamol, 146–47
 - kinetics, 147
 - overdose, 147–48
 - presentation and uses, 147
 - structure, 145
 - toxicity, 147
- parasympathetic nervous system, 187
- parecoxib, 18, 152–53
 - kinetics, 152–53
- paroxetine, 262–63
- partial pressure, inhaled anaesthetics, 106, 107
- passive diffusion, 1–3
 - molecular size, 5
- patient factors, bioavailability influence, 10
- penicillins, 300–04
 - allergy, 304
 - blood–brain barrier crossing, 16
 - classification, 303
 - encephalopathy, 304
 - kinetics, 303
 - mechanism of action, 302–03
 - resistance to, 304
 - side effects, 304
- pentazocine, 141
- peroxisome proliferator-activated receptor- γ , 31, 334
- perphenazine, 273
- pethidine, 17, 138–39
 - effects, 138
 - kinetics, 138–39
 - MAOI interactions, 42
 - presentation, 138
 - uses, 138
- p-glycoprotein (PGP), 4, 41
- pharmaceutical interactions, 40
- pharmaceutical preparation, bioavailability and, 10
- pharmacodynamic drug interactions, 42–44
 - direct, 42
 - indirect, 42
- pharmacokinetics, 50–70
 - applied models, 71–79
 - drug interactions, 10, 40–42, 65–66
 - models, 55–63
 - parameters, 63
- phenanthrene, 90
- phencyclidine, 90, 96
- phenelzine, 263–64
- phenobarbital, 267
- phenothiazines, 271
 - groups, 271, 272
- phenoxybenzamine, 36, 208–09
 - effects, 209
 - kinetics, 209

359 Index

- mechanism of action, 209
- presentation, 208
- uses, 208–09
- phentolamine, 207–08
 - effects, 207–08
 - kinetics, 208
 - presentation, 207
 - uses, 207
- phenylalanine, 81
- phenylbutazone, 149
- phenylephrine, 195–97
 - effects, 197
 - kinetics, 197
 - presentation and uses, 195
- phenyl group, 90
- phenytoin, 41, 265–66
 - digoxin toxicity treatment, 234
 - drug interactions, 266
 - effects, 266
 - kinetics and metabolism, 66, 266
 - mechanism of action, 265
 - uses, 265
- phosphodiesterase(s) (PDEs), 30
- phosphodiesterase inhibitors, 202
 - non-selective, 202–04
 - selective, 204–06
- phospholipase A₂, 336
- phospholipase C, 28
- phospholipid membrane, local anaesthetics
 - crossing, 155, 156
- phosphorus, 291
- physicochemical interactions, bioavailability
 - influence, 10
- physostigmine, 184
- pinocytosis, 5
- pioglitazone, 334
- piperacillin, 303
- piperazine, 90
- piperidine, 91
- placental blood flow, 16
- placental membrane, 16
- plasma, drugs confined to, 15
- platelets, 317
 - NSAID effects on function, 144
 - phosphodiesterase inhibition, 319
 - unfractionated heparin mechanism of action, 322–23
- pneumonic plague, 307
- polyenes, 314
- polypharmacy, elderly people, 24
- porphyric crises, acute, 99
- postoperative nausea and vomiting (PONV), 270, 272, 273, 275, 277
 - see also* antiemetics; nausea; vomiting
- post-synaptic membrane, 166
- post-tetanic potentiation and count, 169–70
- potassium
 - hypokalaemia, 293
 - succinylcholine effects, 172
 - see also* hyperkalaemia
- potassium channel activators, 239–40
- potassium-sparing diuretics, 295
- potentiation drug interactions, 43
- Poynting effect, 113
- prasugrel, 320
- prazosin, 209–10
 - effects, 209–10
 - kinetics, 210
 - presentation and uses, 209
- prednisolone, 336
 - perioperative supplementation, 337–38
- pregabalin, 269
- pregnololone, 97
- pregnancy, drugs during, 17
- prilocaine, 164
 - intravenous regional anaesthesia, 160
 - kinetics, 164
 - presentation and uses, 164
- prions, 299, 300
- probenecid, 43, 303
- procainamide, 230–31
 - kinetics, 231
 - mechanism of action, 231
 - side effects, 231
 - uses, 230
- prochlorperazine, 272–73
 - effects, 273
 - kinetics, 273
 - uses, 272
- pro-drugs, 18
- propafenone, 232–33
 - kinetics, 233
 - mechanism of action, 232
 - presentation and uses, 232
 - side effects, 232–33
- propionic acid, 91
- propofol, 71–72, 75, 101–03, 270
 - Bristol model of TIVA, 73
 - clearance, 65
 - co-administration with midazolam, 43
 - context sensitive half-time, 76
 - effects, 101
 - GABA_A receptors, 96
 - hepatocyte uptake rate, 12

360 Index

- propofol (*cont.*)
 - kinetics, 101–03
 - pharmacokinetics, 71–72
 - presentation, 101
 - structure, 71
 - target-controlled infusion pumps, 75
 - toxicity, 103
 - uses, 101
 - volume of distribution, 64
- propranolol, 215–16, 340
- propionic acids, 149–50
- propylthiouracil, 340
- prostacyclin (PGL₂), 317, 321
- prostaglandin(s), 142
 - synthesis, 142
- prostaglandin analogues, 284–85
- protamine, 324
- protein binding, 7–8
 - barbiturates, 97
 - cephalosporins, 304–05
 - drug interactions, 41
 - drugs with high level, 12
 - drugs with low level, 12
 - fetal and maternal, 16
 - lipophilic nature of sites, 94
 - local anaesthetics, 156, 159
 - neonates, 24
- prothrombin time, 23, 326
- proton acceptors/donors, 6
- proton pump (K⁺/H⁺ ATPase), 282
- proton pump inhibitors, 282–83
- pseudomembranous colitis, 304, 311
- purinergic receptors, ionotropic, 28
- purines, 81
- Px1 and Px2 receptors, 28
- pyrazole, 91
- pyrazolones, 91, 149
- pyridostigmine, 184
- pyrimidines, 81

- quinidine, 226
 - drug interactions, 226
 - kinetics, 226
 - mechanism of action, 226
 - side effects, 226
- quinolones, 307–08
 - kinetics, 307
 - mechanism of action, 307
 - side effects, 307–08
- quinols, 91

- racemic mixtures, 48–49

- ramipril, 249–50
- ranitidine, 42, 281–82
 - effects, 282
 - kinetics, 282
 - mechanism of action, 282
 - uses, 282
- receptors, 26–31
 - agonism, 33–35
 - allosteric modulation of binding, 36
 - altered ion permeability, 26–28
 - antagonism, 35–38
 - classes, 26
 - drug binding dynamics, 32–33
 - drug interaction types, 32
 - general anaesthetic effects, 95
 - metabotropic interactions, 28
 - spare, 36–38
- rectal route, 12
- reduction, phase I reaction, 18
- re-entry mechanisms, 219
- regional anaesthesia, intravenous, 160
- remifentanyl, 72–73, 75, 136–37
 - clearance, 65
 - context sensitive half-time, 72
 - effects, 137
 - elderly people, 24
 - kinetics, 137
 - presentation, 136
 - target-controlled infusion pumps, 75
 - uses, 136–37
- renal disease
 - effects on drug actions, 22–23
 - NSAIDs, 144
- renal excretion, 21–22
- renal replacement therapy, 316
- renal tubules
 - active transport, 4
 - distal, diffusion at, 21
 - proximal, secretion at, 21
 - tight junctions, 1
- renin–angiotensin–aldosterone system, 247–51
 - physiology, 247
- repaglinide, 335
- resting membrane potential, 154
- Reye's syndrome, 146
- rifampicin, 42, 308
 - kinetics, 308
 - mechanism of action, 308
- rifamycins, 308
- ritodrine, 200
- rivaroxaban, 327, 328
- rocuronium, 35, 178–79

361 Index

- chelation, 25
- kinetics, 179
- presentation and uses, 178
- rofecoxib, 91
- ropivacaine, 49, 163–64
 - enantiopure preparations, 49
 - kinetics, 164
 - presentation and uses, 163–64
- route of administration, 9–15
 - epidural, 14–15
 - inhalation *see* inhalation route
 - intramuscular, 12–13
 - intrathecal, 15
 - intravenous *see* intravenous administration
 - oral *see* oral administration
 - rectal, 12
 - subcutaneous, 13
 - sublingual, 12
 - transdermal, 13–14
- ryanodine receptor, 173
- sacral nerve fibres, 187
- salbutamol, 199–200
 - effects, 199–200
 - inhaled, 14
 - kinetics, 200
 - presentation and uses, 199
- salicylates, 92, 145–46
 - see also* aspirin
- salmeterol, 200
- Schnider model of TCI, 74
- selective serotonin reuptake inhibitors (SSRIs), 262–63
- semilogarithmic transformation, exponential
 - wash-out curve, 58
- sequestration, intracellular, 64
- serotonin (5-HT) receptors, 270
- sertraline, 262–63
- sevoflurane, 106, 116–17
 - effects, 117
 - manufacture, 116–17
 - metabolism, 117
 - toxicity, 117
- sildenafil, 246
- single bolus dose models, 55–59
- single twitch stimulation, 168
- sino-atrial node, 218
- skin anaesthesia, 13
- sodium bicarbonate, 42
 - antacid use, 280
 - epidural anaesthetics, 15
 - interaction with calcium, 40
- sodium calcium edetate, 41
- sodium citrate, 280
- sodium ion(s), reabsorption inhibition by
 - diuretics, 292, 294
- sodium ion channel, 154
 - cardiac action potential, 218
 - local anaesthetic binding, 3
 - quinidine blocking, 226
- sodium nitroprusside, 25, 123, 235–37
 - effects, 235
 - kinetics, 236
 - mechanism of action, 235
 - metabolism, 236–37
 - toxicity, 237
 - uses, 235
- sodium thiosulphate, 237
- sodium valproate, 267
- sotalol, 216, 233–34
 - kinetics, 234
 - mechanism of action, 233
 - presentation, 233
 - side effects, 233
 - uses, 233
- spironolactone, 295–96
- Starling equation, 287
- steady-state, 57
- stereoisomerism, 45–48
- stereoisomers, optical, 47–48
- steroids, 336–43
 - antiemetic use, 279
 - anti-inflammatory potential, 336–37, 338
 - feedback loops affecting production, 338
 - inhaled, 14
 - intravenous anaesthesia, 97
 - nucleus, 85
 - perioperative supplementation, 337–38
- stilboestrol, 17
- streptomycin, 310
- structure-activity relationships (SAR), 80
- subcutaneous route, 13
- sublingual route, 12
- succinylcholine, 18, 20, 170–72
 - effects, 171–72
 - genetic polymorphisms, 20
 - kinetics, 171
 - malignant hyperthermia, 173
 - mechanism of action, 171
 - metabolism, 172
 - presentation and uses, 170–71
- succinylcholine apnoea, 174–75
- sucralfate, 284
 - effects, 284

362 Index

- sugammadex, 25, 185–86
 - interactions, 186
 - kinetics, 186
 - presentation and dose, 186
 - side effects, 186
 - uses and mechanism of action, 186
- sugars, 82
- sulphation, 19
- sulphonylureas, 332–33
 - kinetics, 333
 - mechanism of action, 333
 - side effects, 333
 - uses, 333
- summation drug interactions, 43
- supraventricular tachyarrhythmias
 - treatment, 220, 221–26, 228–34
 - verapamil side effects, 224
- sympathetic nervous system, 187–88, 189
- sympathomimetics, 187–206
 - direct-/indirect acting, 189
 - naturally occurring catecholamines, 189–95
 - phosphodiesterase inhibitors, 202–06
 - physiology, 189
 - structure, 189, 196
 - synthetic agents, 195–202
- synergisms, 44
- syringes, drug interactions, 40

- tachyarrhythmias, 218–19
 - AV nodal re-entrant tachycardia, 220
- tachyphylaxis, 38
- tapentadol, 140
- target-controlled infusion pumps (TCI), 73–76
 - decrement time, 76
 - pumps, 73
 - safety, 78–79
- Targinact, 137
- tautomerism, 45, 98
- tazobactam, 303
- teicoplanin, 306
 - side effects, 307
- temazepam, 259–60
- tenoxicam, 150
 - kinetics, 150
- teratogens, 17
- terbutaline, 200
- terminal elimination half-life, 62, 72
- tetanic stimulation, 169
- tetracyclines, 311–12
 - contraindications, 312
- therapeutic index, 12
- thiazides, 92, 292–94
- thiazolidinediones, 334
- thiocyanate (SCN), 236
- thiopental, 17, 97–101
 - effects, 99
 - intra-arterial injection, 100–01
 - kinetics, 17, 100
 - presentation, 98–99
 - uses, 99
- three compartment models, 62, 63
- thrombin, 318
 - inhibitors, direct, 326–27
- thrombolytics, 329–30
- thromboxane, 142
- thromboxane A₂ (TXA₂), 317
- thrombus formation, 317
- thyroid disease, 338–41
- thyroid hormones, 339
 - replacement, 338–40
 - see also* triiodothyronine (T₃)
- thyroxine (T₄), 206, 338–40
 - effects, 339
 - kinetics, 340
 - mechanism of action, 339
 - uses, 339
- ticagrelor, 320
- tight junctions, 1
- time constant, 51, 55, 58, 59, 63
 - natural logarithms, 54
- tinzaparin, 323
- tirofiban, 320
- tissue binding of drugs, 64
- tobramycin, 310
- tolbutamide, 332
 - side effects, 333
- tolerance, 39
- total intravenous anaesthesia (TIVA), 73–76
 - safety, 78–79
- train-of-four, 168, 170
- tramadol, 139–40
 - effects, 139
 - interactions, 139
 - kinetics, 140
 - mechanism of action, 139
 - presentation, 139
- tranexamic acid, 330
- transdermal route, 13–14
- tranylcypromine, 263–64
- triamcinolone, 336
- triazoles, 315
- tricyclic antidepressants, 261–62
 - effects, 261
 - kinetics, 261–62

363 Index

- mechanism of action, 261
- overdose, 262, 265
- uses, 261
- triiodothyronine (T_3), 206, 338
 - kinetics, 340
- tubocurarine, 84
- two-compartment models, 59–62
- tyrosine, 82
- tyrosine kinase, membrane, 31
- urokinase, 329
- vacuum insulated evaporator (VIE), 121–22
- valdecixib, 152–53
 - kinetics, 152–53
- vancomycin, 306
 - oral, 9
 - side effects, 306–07
- vancomycin-intermediate *Staphylococcus aureus* (VISA), 298
- vancomycin-resistant enterococci (VRE), 298
- vancomycin-resistant *Staphylococcus aureus* (VRSA), 298
- vanillylmandelic acid, 193, 194
- vasodilators, 235–46
 - activity and local anaesthetics, 156
 - calcium channel antagonists, 240–44
 - potassium channel activators, 239–40
 - sodium nitroprusside, 235–37
 - see also* nitrates
- vecuronium, 35, 41, 85, 176–78
 - kinetics, 178
 - presentation and uses, 176
- venlafaxine, 263
- ventricular tachyarrhythmias, 220, 226–28
 - with supraventricular tachyarrhythmias, 228–34
- verapamil, 223–24, 240–41
 - kinetics, 224
 - mechanism of action, 224
 - presentation and uses, 224
 - side effects, 224
- vigabatrin, 268–69
- viruses, 298, 299, 313
- vitamin B₁₂, 237
- vitamin K, warfarin therapy, 326
- volatile anaesthetic agents, 14
 - racemic mixtures, 48–49
- volume of distribution, 63–65
 - total, 64
- vomiting, 270
 - domperidone use in children, 284
 - physiology, 270, 271
 - see also* antiemetics
- vomiting centre, 270
- warfarin, 325–26
 - amiodarone effect, 41
 - drug interactions, 41, 325
 - kinetics, 326
 - mechanism of action, 325
 - monitoring of therapy, 326
 - side effects, 325–26
 - uses, 325
- wash-out curve, 51
 - semilogarithmic transformation, 58
- Wolff-Parkinson-White syndrome, 224
- xanthenes, 92
- xenon, 106, 121
 - effects, 121
 - manufacture, 121
- xylidine, 92
- yohimbine, 210
- zaleplon, 260
- zero-order kinetics, 65–66, 66
- zidovudine, 314
 - kinetics, 314
 - mechanism of action, 314
 - side effects, 314
- zolpidem, 260
- zopiclone, 260